Eculizumab is indicated for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) in both adults and children; it was also approved by the U.S. FDA for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to other disease-modifying antirheumatic drugs (DMARDs) or tumor necrosis factor (TNF) antagonists; additionally, it received approval in Japan for the treatment of Castleman's disease (giant lymph node hyperplasia), polyarticular-course juvenile idiopathic arthritis, and systemic-onset juvenile idiopathic arthritis.